$ACAD News

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026

Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target

Top Midday Decliners

UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”

3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI

Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop

ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss

Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%

Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026